메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Gaucher disease is a lysosomal storage disease for which enzyme replacement therapy hasproven to be effective. A switch-over clinical trial was performed to evaluate the efficacyand safety of Abcertin® (ISU Abxis, Seoul, Korea) in subjects with type 1 Gaucher diseasewho were previously treated with imiglucerase. Five Korean patients with type 1 Gaucherdisease were enrolled. Previous doses of imiglucerase ranged from 30 to 55 U/kg everyother week. The same dose of Abcertin® was administered to all patients for 24 weeks. Primary efficacy endpoints were changes in hemoglobin levels and platelet counts, and thesecondary efficacy endpoints included changes in liver and spleen volumes, serumbiomarkers, skeletal status and bone mineral density (BMD). During the study period, nostatistically significant changes were observed in all parameters including hemoglobinlevels and platelet counts, liver and spleen volumes, skeletal status and BMD. Abcertin®administration was continued in three patients for another 24 weeks as an extension of thestudy. Hemoglobin levels and platelet counts were maintained in all three patients. Inconclusion, the efficacy and safety of Abcertin® are similar to those of imiglucerase, andAbcertin® is an effective therapeutic agent for patients with type 1 Gaucher disease(Clinical Trial Registry No. NCT02053896 at www.clinicaltrials.gov).

목차

등록된 정보가 없습니다.

참고문헌 (22)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0